GlassScriptPhysician profile
Cassidy Lorraine Ducray
NPI 1144929084
$862.19
in general payments reported to CMS, 2019-2025
17 companies · $95.64 in 2025
The $95.64 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $114 · 2023: $27.53 · 2024: $625 · 2025: $95.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $152.72 | 2024 | Biomonitor, Solia |
| Novo Nordisk INC | $133.27 | 2022-2025 | Ozempic |
| Biosense Webster, INC. | $114.12 | 2024 | Carto 3, Qdot Micro Catheter |
| Teva Pharmaceuticals USA, INC. | $62.11 | 2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $55.00 | 2024 | Invega |
| Otsuka America Pharmaceutical, INC. | $48.76 | 2024-2025 | Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $41.27 | 2024-2025 | Vivitrol |
| Vanda Pharmaceuticals INC. | $40.87 | 2024 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $36.67 | 2024 | |
| Neurocrine Biosciences, INC. | $36.51 | 2024-2025 | Ingrezza |
| Shield Therapeutics INC | $27.53 | 2023 | Accrufer |
| Indivior INC. | $24.63 | 2024 | Perseris |
| Astellas Pharma US INC | $21.85 | 2025 | Veozah |
| Abbvie INC. | $19.89 | 2024 | |
| Inspire Medical Systems, INC. | $17.75 | 2024 | Inspire |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $15.69 | 2024 | Auvelity |
| Hologic Sales and Service, LLC | $13.55 | 2024 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassidy Ducray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.